Orphan drugs: major development challenges at the clinical stage
- 1 March 2019
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (3) , 867-872
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A model‐based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophyBritish Journal of Clinical Pharmacology, 2016
- Orphan diseases: state of the drug discovery artWiener Medizinische Wochenschrift, 2016
- Drug Development and Challenges for Neuromuscular Clinical TrialsJournal of Molecular Neuroscience, 2015
- The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trialsExpert Review of Respiratory Medicine, 2015
- A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.govOrphanet Journal of Rare Diseases, 2014
- Innovative research methods for studying treatments for rare diseases: methodological reviewBMJ, 2014
- Coping with small populations of patients in clinical trialsExpert Opinion on Orphan Drugs, 2014
- Orphan drugs: the regulatory environmentDrug Discovery Today, 2013
- Rare diseases, orphan drugs and their regulation: questions and misconceptionsNature Reviews Drug Discovery, 2010
- Orphan drug development is progressing too slowlyBritish Journal of Clinical Pharmacology, 2006